With the ubiquity of digital signage on the rise, new frontiers like the convergence of AV and IT and the explosion of VoT are on the horizon. Larry O’Hagan, Inside Sales Associate for NanoLumens, joined us this episode to talk about why AV and IT need to learn from each other, why he thinks VoT devices are the future. “This makes a visual impact statement upon people,” O’Hagan said.
He gives us some examples of how digital signage is evolving and innovating in different industries. In addition, Larry also opens up about why color spacing and flexibility are given such great focus at companies like NanoLumens. “Typically, it’s the first time they’ve seen something like this [and] they tend to remember the content that’s being displayed to them, simply because it’s on an unusual background, whether they consciously realize that or not,” O’Hagan said.
For the latest news, videos, and podcasts in the Pro AV Industry, be sure to subscribe to our industry publication. A new episode of the Pro AV Show drops every Thursday.
Follow us on social media for the latest updates in B2B!
Twitter – @ProAVMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
Demand for AV integration services is becoming more complex and widespread, making it increasingly difficult for integrators to scale operations without sacrificing profitability. According to AVIXA’s 2024 Industry Outlook and Trends Analysis, the Pro AV market is projected to reach $422 billion by 2029, intensifying the need for flexible, scalable support. Amid these pressures, service…
The Pro AV industry continues to intersect with sectors like healthcare, retail, and corporate environments, making access to hands-on product demos and direct vendor conversations more important than ever. Technologies are evolving rapidly, and end users are demanding increasingly complex solutions. According to AVIXA, the global Pro AV market is projected to reach $402…
